ZEB1 and glioblastoma: Another recent study revealed that IL‐24 administration increased the expression of the epithelial marker E‐Cadherin and suppressed Zeb1 in glioblastoma multiforme (GBM) cell lines, leading to increased sensitivity to temozolomide.